Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

Anitria Cotton, Ryan Collinson, Lynne Wilson, Zi Yun Ng, Hun S Chuah, Michael F. Leahy, Rebecca Howman, Carolyn Grove, Hasib Sidiqi, Malcolm Webb, Darren Boey, Olivia Ruhen, Michael Phillips, Matthew Linden, Kathy Fuller, Wendy N. Erber, Ronald Hoffman, John D. Crispino, Belinda Guo

Blood (2023) 142 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2023-182140

Published: 2023

Journal Articles

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood (2022) 140 (Supplement 1): 9677–9680.

https://doi.org/10.1182/blood-2022-162547

Published: 2022

Journal Articles

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Shaun Fleming, John Reynolds, Ashish Bajel, Nicola Venn, John Kwan, John Moore, David T Yeung, Nalini Pati, Michael F. Leahy, Joanna Nkyekyer, Emma Verner, Leanne Berkahn, Rosemary Sutton, Andrew H. Wei, Matthew Greenwood

Blood (2021) 138 (Supplement 1): 1234.

https://doi.org/10.1182/blood-2021-151826

Published: 2021

Journal Articles

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Portia Smallbone, MBBS, Stephanie Clugston, MBBS (Hons), Rebecca De Kraa, BSc, Duncan Purtill, MBBS,FRCPA,FRACP, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-141783

Published: 2020

Journal Articles

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Stephanie Clugston, MBBS (Hons), Portia Smallbone, MBBS, Duncan Purtill, MBBS,FRCPA,FRACP, Dustin Hall, MBBS,FRCPA,FRACP, Rebecca De Kraa, BSc, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141784

Published: 2020

Journal Articles

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Shaun Fleming, MBBS,, Nicola Venn, BSc, John Reynolds, PhD, Uyen Nguyen, John Kwan, MBBS,FRACP,FRCPA, John Moore, MDFRACP,FRCPA, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Michael F. Leahy, MBChB, FRACP, FRCPath, FRCP, Matthew Greenwood, MBBS, FRACP, FRCPA, Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Ashish Bajel, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Rosemary Sutton, BSc MSc PhD

Blood (2019) 134 (Supplement_1): 1300.

https://doi.org/10.1182/blood-2019-132048

Published: 2019

Journal Articles

Survival of Patients with Multiple Myeloma in Western Australia, a Large State of 2.5 Million Square Kilometers: A Population Based Study

Teng Fong Ng, BSc, MBBS, MRCP, Michael F. Leahy, MBChB, FRACP, FRCPath, FRCP, Bradley Augustson, MBBS FRACP FRCPA, Sally Burrow, BMATH GradDipMedStat, Philip Vlaskovsky, BSc, PGDipSci, MSc, Ben Carnley, MBBS, FRACP, FRCPA, Matthew P.F. Wright, MBBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 3552.

https://doi.org/10.1182/blood-2018-99-112148

Published: 2018

Journal Articles

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

James Anton Kuzich, MBBS, Andrew Peter Hutchison, MBBS, Kenneth Lim, MBBS, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Gavin Cull, MB, BS, FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, David John Longstaff Joske, Dejan Radeski, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP

Blood (2017) 130 (Supplement 1): 1524.

https://doi.org/10.1182/blood.V130.Suppl_1.1524.1524

Published: 2017

Journal Articles

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S. Tam, MD, Hang Quach, MBBS, MD, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, MD FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, Richard Eek, MBCHB, Nicholas Wickham, FRCPA,FRACP,FRCPath, Sushrut S. Patil, FRACP, FRCPA, Jane Huang, MD, Xiaoping Zhang, MD PhD, Lai Wang, PhD, Eric Hedrick, MD, William Novotny, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 1745.

https://doi.org/10.1182/blood.V130.Suppl_1.1745.1745

Published: 2017

Journal Articles

First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131 I-Rituximab: The INITIAL Study,

Andrew D McQuillan, MBBS FRACP FRCPA, William BG Macdonald, MBBS FRACP, Michael F Leahy, J Harvey Turner, MD FRACP

Blood (2011) 118 (21): 3719.

https://doi.org/10.1182/blood.V118.21.3719.3719

Published: 2011

Journal Articles

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131 I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

Michael F. Leahy, J. Harvey Turner

Blood (2011) 117 (1): 45–52.

https://doi.org/10.1182/blood-2010-02-269753

Published: 2011

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

Repeat Treatment with Iodine-131-Rituximab Is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma (NHL) Who Had Previously Responded to This Therapy.

Mark J. Bishton, MB, ChB, Michael F. Leahy, Rod J. Hicks, J. Harvey Turner, Ad McQuillan, John Francis Seymour

Blood (2007) 110 (11): 3413.

https://doi.org/10.1182/blood.V110.11.3413.3413

Published: 2007

Journal Articles

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes

Blood (2004) 104 (9): 2926–2932.

https://doi.org/10.1182/blood-2004-03-1134

Published: 2004

NARROW

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Survival of Patients with Multiple Myeloma in Western Australia, a Large State of 2.5 Million Square Kilometers: A Population Based Study

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131 I-Rituximab: The INITIAL Study,

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131 I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Repeat Treatment with Iodine-131-Rituximab Is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma (NHL) Who Had Previously Responded to This Therapy.

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only